Trevi Therapeutics, Inc. Increase (Decrease) in Prepaid Expense and Other Assets
Trevi Therapeutics, Inc. (TRVI) reported Increase (Decrease) in Prepaid Expense and Other Assets of $5.77 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets · last filed 2026-08-06
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-06-30 was $2.93M, a 192.91% increase year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2026-03-31 was $2.84M, a 369.09% increase year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-12-31 was -$158.00K, a 305.19% decline year-over-year.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for the quarter ending 2025-09-30 was $30.00K.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2025 was $1.48M.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2024 was -$2.66M, a 193.30% decline from fiscal 2023.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2023 was $2.85M, a 374.21% increase from fiscal 2022.
- Trevi Therapeutics, Inc. increase (decrease) in prepaid expense and other assets for fiscal 2022 was $601.00K.
| Period end | Increase (Decrease) in Prepaid Expense and Other Assets 3 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month | Increase (Decrease) in Prepaid Expense and Other Assets 6 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 9 month | Increase (Decrease) in Prepaid Expense and Other Assets 9 month as first filed | Increase (Decrease) in Prepaid Expense and Other Assets 12 month |
|---|---|---|---|---|---|---|
| 2026-06-30 | $2.93M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $5.77M 10-Q · filed 2026-08-06 | $5.61M derived: sum of 3 quarters · filed 2026-08-06 | $5.64M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2026-03-31 | $2.84M 10-Q · filed 2026-05-05 | $2.68M derived: sum of 2 quarters · filed 2026-05-05 | $2.71M derived: sum of 3 quarters · filed 2026-05-05 | $3.71M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-12-31 | -$158.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$128.00K derived: sum of 2 quarters · filed 2026-03-17 | $873.00K derived: sum of 3 quarters · filed 2026-08-06 | $1.48M 10-K · filed 2026-03-17 | ||
| 2025-09-30 | $30.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | $1.03M derived: sum of 2 quarters · filed 2026-08-06 | $1.64M 10-Q · filed 2025-11-13 | $1.71M derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $1.61M 10-Q · filed 2026-08-06 | $1.68M derived: sum of 3 quarters · filed 2026-08-06 | $861.00K derived: sum of 4 quarters · filed 2026-08-06 | ||
| 2025-03-31 | $605.00K 10-Q · filed 2026-05-05 | $682.00K derived: sum of 2 quarters · filed 2026-05-05 | -$140.00K derived: sum of 3 quarters · filed 2026-05-05 | -$1.47M derived: sum of 4 quarters · filed 2026-05-05 | ||
| 2024-12-31 | $77.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | -$745.00K derived: sum of 2 quarters · filed 2026-03-17 | -$2.08M derived: sum of 3 quarters · filed 2026-03-17 | -$2.66M 10-K · filed 2026-03-17 | ||
| 2024-09-30 | -$822.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-13 | -$2.15M derived: sum of 2 quarters · filed 2025-11-13 | -$2.74M 10-Q · filed 2025-11-13 | -$2.82M derived: sum of 4 quarters · filed 2025-11-13 | ||
| 2024-06-30 | -$1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.91M 10-Q · filed 2025-08-07 | -$2.00M derived: sum of 3 quarters · filed 2025-08-07 | -$1.55M derived: sum of 4 quarters · filed 2025-08-07 | ||
| 2024-03-31 | -$584.00K 10-Q · filed 2025-05-08 | -$669.00K derived: sum of 2 quarters · filed 2025-05-08 | -$223.00K derived: sum of 3 quarters · filed 2025-05-08 | $1.43M derived: sum of 4 quarters · filed 2025-05-08 | ||
| 2023-12-31 | -$85.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-18 | $361.00K derived: sum of 2 quarters · filed 2025-03-18 | $2.01M derived: sum of 3 quarters · filed 2025-03-18 | $2.85M 10-K · filed 2025-03-18 | ||
| 2023-09-30 | $446.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.10M derived: sum of 2 quarters · filed 2024-11-06 | $2.94M 10-Q · filed 2024-11-06 | $2.96M derived: sum of 4 quarters · filed 2024-11-06 | ||
| 2023-06-30 | $1.65M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $2.49M 10-Q · filed 2024-08-08 | $2.51M derived: sum of 3 quarters · filed 2024-08-08 | $2.20M derived: sum of 4 quarters · filed 2024-08-08 | ||
| 2023-03-31 | $836.00K 10-Q · filed 2024-05-07 | $858.00K derived: sum of 2 quarters · filed 2024-05-07 | $544.00K derived: sum of 3 quarters · filed 2024-05-07 | $1.86M derived: sum of 4 quarters · filed 2024-05-07 | ||
| 2022-12-31 | $22.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-20 | -$292.00K derived: sum of 2 quarters · filed 2024-03-20 | $1.02M derived: sum of 3 quarters · filed 2024-03-20 | $601.00K 10-K · filed 2024-03-20 | ||
| 2022-09-30 | -$314.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $999.00K derived: sum of 2 quarters · filed 2023-11-09 | $579.00K 10-Q · filed 2023-11-09 | $492.00K 10-Q · filed 2022-11-10 | $115.00K derived: sum of 4 quarters · filed 2023-11-09 | |
| 2022-06-30 | $1.31M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $893.00K 10-Q · filed 2023-08-10 | $885.00K 10-Q · filed 2022-08-11 | $429.00K derived: sum of 3 quarters · filed 2023-08-10 | -$41.00K derived: sum of 4 quarters · filed 2023-08-10 | |
| 2022-03-31 | -$420.00K 10-Q · filed 2023-05-11 | -$884.00K derived: sum of 2 quarters · filed 2023-05-11 | -$1.35M derived: sum of 3 quarters · filed 2023-05-11 | -$83.00K derived: sum of 4 quarters · filed 2023-05-11 | ||
| 2021-12-31 | -$464.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | -$934.00K derived: sum of 2 quarters · filed 2023-03-16 | $337.00K derived: sum of 3 quarters · filed 2023-03-16 | -$342.00K 10-K · filed 2023-03-16 | ||
| 2021-09-30 | -$470.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $801.00K derived: sum of 2 quarters · filed 2022-11-10 | $122.00K 10-Q · filed 2022-11-10 | -$297.00K derived: sum of 4 quarters · filed 2022-11-10 | ||
| 2021-06-30 | $1.27M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $592.00K 10-Q · filed 2022-08-11 | $173.00K derived: sum of 3 quarters · filed 2022-08-11 | -$74.00K derived: sum of 4 quarters · filed 2022-08-11 | ||
| 2021-03-31 | -$679.00K 10-Q · filed 2022-05-12 | -$1.10M derived: sum of 2 quarters · filed 2022-05-12 | -$1.34M derived: sum of 3 quarters · filed 2022-05-12 | -$362.00K derived: sum of 4 quarters · filed 2022-05-12 | ||
| 2020-12-31 | -$419.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-17 | -$666.00K derived: sum of 2 quarters · filed 2022-03-17 | $317.00K derived: sum of 3 quarters · filed 2022-03-17 | -$742.00K 10-K · filed 2022-03-17 | ||
| 2020-09-30 | -$247.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $736.00K derived: sum of 2 quarters · filed 2021-11-10 | -$323.00K 10-Q · filed 2021-11-10 | |||
| 2020-06-30 | $983.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | -$76.00K 10-Q · filed 2021-08-12 | ||||
| 2020-03-31 | -$1.06M 10-Q · filed 2021-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |